Table 3.
Clinical application of Sugemule-10.
| Disease syndrome | No. | Control group | Sgml-10 treatment group | Clinical efficacy | Course of treatment | References |
|---|---|---|---|---|---|---|
| Renal calculi | 30 | – | Sgml-10 + Sema-3 Decoction | Cure rate 90 %; improvement rate 6.66 %; inefficiency 3.33 % |
12 days/course | (Bao & Han, 2000) |
| Urolithiasis | 22 | – | Sgml-10 + Sema-3 Decoction | Cure rate 86.4 %; improvement rate 9.1 %; inefficiency 4.5 % |
1–20 days | (Ming & Da, 2009) |
| UTI | 100 | – | Morning: Sgml-10 + Xiriiga-4 Decoction; Noon: Xirimaodu-8; at night: Saligaridi + Xiriga-4 Decoction |
Cure rate 93 %; were markedly effective; two were ineffective; total effective rate 98 % |
7 days/course; general treatment is 4–6 courses |
(Kong & Kong, 2000) |
| UTI | 50 | – | Yizhi Wenshen Shi wei Pill Sa Li Chong |
Cure rate was 82 %; significant rate 10 %; improvement rate 8 %; total effective rate 100 % |
Average treatment 1.5 months | (Li, 2012) |
| DMUTI | – | Sgml-10 Tonglaga-mu5/Gurigumu-13 |
Significantly improve clinical symptoms | (Wu, 2014) | ||
| NS | 38 | – | Morning: Bai Kou-13; Noon: Sgml-10/Jili-3; Evening: Sa Li Chong |
Cure rate 65.8 %; improvement rate 23.7 %; inefficiency 10.7 %; total effective rate 89.5 % |
3 months/course | (Si, Li, & Qi, 1996) |
| CRF | 62 | – | Sgml-10, Narenmandula-11, Saligarudi, BugrenArula −10, Sema-3, Xiriga-4 |
Effective rate 8 %; improvement rate 90.3 %; invalid rate 1.6 %; total effective rate 98.3 % |
Symptoms and biochemical indexes improved significantly after 1 month | (Bao et al., 2003) |
| DN | 80 | control the blood glucose leve + ACEI/ARB, statins/fibrates, Aspirin/Jinshuibao Capsules |
Basic treatment + Zhenbao Pill/ Sarigaridi, /Sgml-10 |
Total effective rate: 95 % Sgml-10 group vs control group, P < 0.05 |
1 month/course | (Hu et al., 2018) |
| HSPN | 1 | – | Sgml-10, Buren Aru −10, | Reduced edema, normal urinary volume, improved biochemical indicators |
44 days | (Yi & Chen, 2014) |
| AGN | 63 | Conventional treatment (diuresis, antihypertensive) |
conventional treatment + sgml-10 \Xieriga −4 Decoction |
Total effective rate 91.89 %; treatment group is better than control group (P < 0.05) |
4 weeks | (Wu & Shi,2010) |
| CGN | 40 | Benazepril, Hydrochlorothiazide, Aspirin |
Control treatment + sgml-10/ Narenmandula, with Sema-3 |
Total effective rate is higher than control group (P < 0.05) |
4 months | (Wu, 2015) |
Note: Sema-3 Decoction: It is composed of tribulus, Malvae Fructus and crab. Xirimaodu-8: It is composed of 100 g phellodendron, 40 g liquorice, piper, Moschus, 25 g gardenia and safflower, 75 g Chinese ink and bear bile; Saligaridi and Sa Li Chong are different names for the same formular, which is composed of Terminalia chebula Retz., elecampane, aconitum and cardamom, calamus and Silver vermilion, Moschus, Hollyhock Flower and Canavalie Semen, 175 g each, Chinensis Cassia and black cloud loquat leaves 12 g each, Violetgrass 22 g each madder ink, bear bile and red flower 5 g each. Tonglaga-5: By pomegranate 35 g cinnamon, cardamom, each 5 g red flower 20 g with; Gurigumu-13 is composed of saffron 10 g clove, bezoar, Moschus, hornbill horn, silver vermilion, red sandalwood, T. chebula, Melia chinensis, Gardenia jasminoides and Osmanthus xylanthus 5 g each; CRF: Chronic renal failure; CGN: Chronic glomerulonephritis; AGN: Acute glomerulonephritis; NS: Nephrotic syndrome; UTI: Urinary tract infection; DMUTI: Diabetes with urinary tract infection; HSPN: DN: Diabetic Nephropathy.